Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 23 of 23 entries
View as:

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT05404529 Org: User:
Start: 04/29/22 End: 01/24/23 Due: 01/24/24

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05106309 Org: User:
Start: 12/29/21 End: 02/24/22 Due: 02/24/23

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04241393 Org: User:
Start: 02/04/20 End: 11/08/20 Due: 11/08/21

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04232878 Org: User:
Start: 12/16/19 End: 05/21/20 Due: 05/21/21

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Phase: N/A Priority: Normal
NCT ID: NCT04787302 Org: User:
Start: 06/01/21 End: 07/14/23 Due: 07/14/24

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT05404542 Org: User:
Start: 05/10/22 End: 08/14/23 Due: 08/14/24

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05965219 Org: User:
Start: 08/15/23 End: 11/10/23 Due: 11/10/24

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05123079 Org: User:
Start: 11/02/21 End: 12/07/21 Due: 12/07/22

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06435923 Org: User:
Start: 05/29/24 End: 07/03/24 Due: 07/03/25

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05245539 Org: User:
Start: 01/24/22 End: 11/14/22 Due: 11/14/23

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06301971 Org: User:
Start: 03/04/24 End: 04/04/24 Due: 04/04/25

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06366243 Org: User:
Start: 05/10/24 End: 06/20/24 Due: 06/20/25

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05915546 Org: User:
Start: 06/08/23 End: 07/26/23 Due: 07/26/24

A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04592536 Org: User:
Start: 10/06/20 End: 12/13/21 Due: 12/13/22

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05138653 Org: User:
Start: 10/18/21 End: 01/23/23 Due: 01/23/24

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05933187 Org: User:
Start: 07/19/23 End: 09/12/23 Due: 09/12/24

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05610189 Org: User:
Start: 12/15/22 End: 12/17/23 Due: 12/17/24

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05581823 Org: User:
Start: 10/19/22 End: 02/02/23 Due: 02/02/24

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT04136873 Org: User:
Start: 10/15/19 End: 06/03/21 Due: 06/03/22

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04295642 Org: User:
Start: 01/08/20 End: 07/23/21 Due: 07/23/22

Fixed-Dose Trial in Early Parkinson's Disease (PD)

Phase: N/A Priority: Normal
NCT ID: NCT04201093 Org: User:
Start: 12/13/19 End: 06/28/24 Due: 06/28/25

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05824143 Org: User:
Start: 04/17/23 End: 07/07/23 Due: 07/07/24

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Phase: N/A Priority: Normal
NCT ID: NCT05547542 Org: User:
Start: 03/02/23 End: 08/06/24 Due: 08/06/25